Immunocore Holdings plc (IMCR) Cash Flow Statement

The gap between net income and operating cash flow is heavily influenced by working capital swings, as seen in 2026Q1 where a $29.8M negative working capital change drove OCF to -$13.8M despite a $13.0M net income. This suggests that reported earnings are not yet a reliable indicator of cash generation, and investors should focus on the underlying cash burn from operations. The positive OCF/NI ratios in some quarters (e.g., 6.78 in 2026Q2) are misleading due to the small net income base, highlighting the need to normalize for working capital volatility.

The erratic FCF pattern is typical of a commercial-stage biotech scaling KIMMTRAK sales while managing clinical trial costs. The positive FCF quarters in 2025Q2 and 2024Q3 were driven by favorable working capital movements, not sustainable operations, as evidenced by the negative FCF in most recent quarters. As revenue grows 20% YoY, the trajectory suggests FCF could stabilize if working capital swings moderate, but the current volatility warrants caution.

The extremely low capital intensity (CapEx/Revenue below 4% in all quarters) indicates that the company's growth is not constrained by physical asset expansion, consistent with a high-margin, outsourced manufacturing model. This allows nearly all revenue to flow to gross margin, but the real cash drain is R&D and working capital, not capex. Investors should monitor whether pipeline expansion into PRAME requires higher manufacturing investment, which could alter this favorable dynamic.

The large swings in working capital, particularly in accounts receivable and inventory, appear to be driven by the lumpy nature of collaboration milestone payments and specialty pharmacy ordering patterns. The negative working capital changes in 2026Q1 and 2025Q4 suggest cash outflows for inventory or receivables build-up, while positive changes in 2025Q2 and 2024Q2 indicate collections of large receivables. This volatility obscures the underlying operational cash burn, and investors should normalize for these swings to assess true cash generation.

The absence of shareholder returns is consistent with a company prioritizing pipeline expansion, particularly the PRAME program, over returning capital. With $467.7M in cash and a narrowing operating loss, the company appears to have sufficient runway, but the negative operating cash flow in most quarters implies continued cash consumption. Investors should monitor whether the cash balance can fund the Phase III trials without dilution, as the recent EPS miss suggests expenses may be running ahead of revenue.

The positive divergence between cumulative OCF and net income is largely due to non-cash charges like SBC and D&A, which totaled over $70M in the period, offsetting working capital outflows. This suggests that the accounting losses overstate the actual cash drain, but the company still consumed $26.5M in operating cash over the period. As revenue scales, the gap should narrow, but the recent quarters show renewed cash burn, warranting close monitoring of the trajectory.